Applied Molecular Evolution (AME) is part of the Lilly Biotechnology Center of San Diego. AME is a leader in applying directed molecular evolution to improve healthcare by discovering, optimizing and developing human biotherapeutics. Since its inception, AME’s principal focus has been on applying its proprietary AMEsystem™ technology platform to the full range of protein therapeutic candidates including antibodies, cytokines, hormones and enzymes to develop novel human biotherapeutic candidates.Since February 2004, AME has been a wholly-owned subsidiary of Eli Lilly and Company and is an integral part of Lilly’s research organization. Lilly, a leading innovation-driven corporation is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

FLAVORx, Inc. company offers a medical flavoring system which makes medicine more palatable for children, (and some adults). The company doesn't neglect our furry friends either, as the product is also available to veterinarians. Using 42 flavors to sweeten some 600 human and nearly 400 animal medications, FLAVORx sells its products to about 35,000 pharmacies located in the US, as well as in Australia, the Bahamas, Canada, and New Zealand. CEO Kenny Kramm started the company out of the need to hide the bitter taste of his daughter's cerebral palsy medicine.

Jiangbo Pharmaceuticals, Inc. (Jiangbo), formerly Genesis Pharmaceuticals Enterprises, Inc., is a holding company. The Company operates, controls and owns the pharmaceutical business of Laiyang Jiangbo Pharmaceutical Co., Ltd. (Laiyang Jiangbo). Laiyang Jiangbo researches, develops, manufactures, markets and sells pharmaceutical products and health supplements in the PRC. Laiyang Jiangbo produces tablets, capsules, granules, syrup and electuary for both Western medical drugs and Chinese herbal-based medical drugs. Approximately 35% of its products are Chinese herbal-based drugs and 65% are Western medical drugs. In February 2009, the Company acquired Shandong Hongrui Pharmaceutical Factory (Shandong Hongrui).

Archemix Corp., a biotechnology company, engages in discovering, developing, and commercializing aptamer therapeutics for the prevention and treatment of chronic and acute diseases in Massachusetts. The company’s aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. It also offers product candidates for cardiovascular, hematology, and oncology diseases. Archemix Corp. was incorporated in 2000 and is based in Cambridge, Massachusetts.

Vaxon Biotech is a biopharmaceutical company focused on the treatment of cancers and related malignancies. Disease targets include breast, lung, pancreatic, and prostate cancer. The company's claim to fame is its development of optimized cryptic peptide antigens (substances that trigger protein responses in the immune system), which have shown early progress in the immune response against these cancers. The company's development products are classified as therapeutic vaccines and are developed to trigger the immune system to attack malignant cells in solid tumors while steering clear from normal cells.

Paladin Labs Inc. company's slate of prescription offerings includes drugs for urology, endocrinology, cancer, dermatology, neurology, and women's health. Among Paladin's key products are prostate cancer treatment Trelstar, testosterone deficiency drug Testim, and osteoarthritis therapy Pennsaid. The company also offers some over-the-counter (OTC) drugs in Canada, including emergency contraceptive Plan B. The company focuses on serving markets that are overlooked by larger pharmaceutical firms, typically by forming developing and marketing partnerships with other drugmakers.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

Hana Biosciences, Inc. company was founded in 2002 and is based in South San Francisco, California. Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The company's supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer.

Lyne Laboratories contract pharmaceutical manufacturer specializes in oral liquid formulations (with a bitter-taste blocker available), as well as powder-form, semi-solid, and tablet medicines. The company also offers analytical services, such as quality control and testing, and regulatory support services. Lyne Laboratories can whip up small test-size batches for clinical research as well as full production for commercial launches and provide regulatory support along the way. An explosion-proof production and storage facility has expanded its ability to produce flammable drugs.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.